Stay updated on Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The page now displays the latest revision label (v3.4.3) and removes the previous revision (v3.4.2).
    Difference
    0.0%
    Check dated 2026-03-07T13:20:11.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    32 days ago
    Change Detected
    Summary
    The page shows a revision bump from v3.4.1 to v3.4.2 with no changes to study content, eligibility criteria, endpoints, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-13T17:25:19.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    A minor revision update from v3.4.0 to v3.4.1; core study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-06T13:37:56.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    Minor UI and text updates: glossary show/hide controls were added, and footer text was updated to reflect capitalization and a new revision tag (v3.4.0).
    Difference
    0.2%
    Check dated 2026-01-23T10:14:44.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    Revision label updated from v3.3.3 to v3.3.4. No substantive study information or functionality appears to be affected.
    Difference
    0.0%
    Check dated 2026-01-16T05:59:56.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    Added a comprehensive Locations section listing study sites across multiple states (Alabama, Arizona, California, Colorado, District of Columbia, Florida, Kentucky, Louisiana, Maryland, Massachusetts, Minnesota, Montana, Nebraska, Nevada, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Texas, Utah, Washington) and included the Revision: v3.3.3 label.
    Difference
    2%
    Check dated 2025-12-24T14:34:57.000Z thumbnail image

Stay in the know with updates to Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial page.